Registration
Follow us on
  • Linkedin
  • Twitter
  • Facebook
  • Google+
avi treves

Avi Treves, PhD

15:00|Session 12 (Stage 3)

Stem Cells and Immunotherapy – Translational Development from Bench to Industry

Dr. Avi Treves’ main areas of expertise include: cell therapies and stem cell technologies, cancer immunotherapy, translational research and clinical development in stem cells and regenerative medicine, business development of biotech companies.

As Deputy Director of the Cancer Research Center at the Sheba Medical Center in Israel, Avi Treves operates the Ella Institute for Treatment and Research of Melanoma, Stem Cells Translational Laboratory at the Sheba Center for Regenerative Medicine; Good tissue culture practice (GTP) facility, development and production of cell based products, and the Family Cord Blood Bank’s  clinical applications.
 
Dr. Treves leads significant research and development programs for medical applications of adult stem cells from various sources such as peripheral blood, bone marrow, cord blood and adipose tissue, with the clinical aim to treat degenerative diseases such as cardiovascular ischemia, diabetic ulcers and retinal diseases.
 
Dr. Avi Treves is also a co-investigator in the adoptive immunotherapy program of melanoma, a cell based therapy project in its clinical phase.
He is an expert in translational research, regulation and developing cell based technologies, products and their clinical applications, business development, and funding of biotech projects.
 
He is adviser and scientific board member for biotech companies (Pluristem Therapeutics; SeraCare Life Sciences Inc.; Taburit Ltd.; Kalia Industries; Van Leer Technology Ventures – Jerusalem Ltd. GluSense Ltd.) and co-author of more than 90 scientific publications and 10 patents.
 
Avi Treves is member of the Israeli Ministry of Health Committee for Registering of Cellular Based Therapies; the Translational Research and Commercialization Committee of the (Chairman) Israel Stem Cells Society; and of the Commercialization Committee of the International Society for Cellular Therapy (ISCT).
 
Previously, he was founder and CEO of BioRegenerate Inc.,Gamida Cell Ltd.; Hadasit Ltd. (the technology transfer company of the Hadassah Medical Center); Head of the R&D Division of the Hadassah Medical Center and adviser for biotech companies. Gamida Cell Ltd. is now in phase III clinical study of its first product, based on ex vivo expanded hematopoietic stem cells, for bone marrow transplantation.  
 
He got his PhD from the Weizmann Institute of Science, Israel; and did his Post-doctoral studies at Stanford University Medical School, CA USA.